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Abstract Concomitant with the extensive growth and
differentiation of the mammary epithelium during preg-
nancy and lactation, and epithelial involution after
weaning, the vasculature of the mammary gland under-
goes repeated cycles of expansion and regression.
Vascular expansion is effected by sprouting angiogenesis,
intussusception and conceivably also vasculogenesis. The
capacity of the epithelial cells to stimulate vascular
growth and differentiation is dependent on the constella-
tion of systemic and local hormones and growth factors
as well as the changing demands for oxygenation and
nutrient supply. This results in the release of angiogenic
factors which stimulate endothelial cell growth and
regulate vascular architecture. In contrast to the angio-
genic phase of the mammary gland cycle, little is known
about the control of vascular regression although this
would possibly offer new insights into therapeutic
possibilities against breast cancer. In this review we
summarize knowledge regarding the mechanisms regulating
the vasculature of the mammary gland and delineate the
importance of the vasculature in the attainment of organ
function. In addition, we discuss the angiogenic mechanisms
observed during mammary carcinogenesis and their conse-
quences for breast cancer therapy.
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Abbreviations
VEGF vascular endothelial growth factor
MMP matrix metalloprotease
hif hypoxia-inducible factor
HEXIM hexamethylene bisacetamid-inducible protein
CAM cell adhesion molecule
MMTV mouse mammary tumor virus
SDF stroma-derived factor
CCL chemokine (C-C motif) ligand
The mammary gland cycle is unique among all organs of
the body because its development mainly occurs post-
natally and its organ structure changes repeatedly and
drastically according to the hormonal environment and
functional demands. In particular, the dramatic expansion
of the parenchyma at the expense of the stromal/adipose
tissue during pregnancy and the high secretory and
metabolic activity of the epithelium during lactation
impose a drastic change in the supply of oxygen,
nutrients and fluid. Therefore, by necessity, not only the
mammary parenchyma but also the mammary vasculature
has to adapt repeatedly to the functional state of the
organ. A similar situation can be observed in the ovary
when the post-ovulatory follicle is converted to the
glandular corpus luteum responsible for high progester-
one synthesis and needs extensive vascularization. The
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important difference, however, lies in the fact that the
corpus luteum degenerates when its function is no longer
needed, whereas the mammary gland reverts to a
quiescent state in preparation for a subsequent cycle of
pregnancy and lactation. Thus, the mammary gland cycle
gives a unique opportunity to study not only vascular
expansion but also the controlled vascular regression as
occurs during postlactational involution.
Vascular Network Formation
The development of blood vessels is critical for the
maintenance of every functional organ system. Vascular
development is mainly executed during embryogenesis,
while post-natally it is limited to sites of injury and organs
undergoing functional adaptation such as the hairy skin and
the female reproductive organs. Moreover, vascular devel-
opment plays a crucial role in many pathological con-
ditions, most prominently during carcinogenesis. In the
course of blood vessel formation two distinct processes are
effective: vasculogenesis defining the de-novo formation of
blood vessels from undifferentiated precursor cells, and
angiogenesis that represents the formation of new vessels
from pre-existing ones. Angiogenesis can then be further
divided into sprouting and intussusceptive angiogenesis.
Sprouting angiogenesis was the first angiogenic mecha-
nism discovered and can be divided into five distinct steps:
(1) evasion of endothelial cells from their present location
in the vessel wall, (2) endothelial proliferation, (3) guided
migration and branching through the tissue, (4) three-
dimensional organization and tube formation and (5)
recruitment of perivascular cells to attain their venous or
arterial identity [1]. The main characteristics of sprouting
angiogenesis, endothelial proliferation and the acquisition
of an invasive phenotype are controlled by a multitude of
angiogenic growth factors and matrix proteases, which are
released in response to metabolic stimuli such as hypoxia or
hypoglycaemia and to mechanical signals such as blood
pressure and inflammation. In particular, vascular endothe-
lial growth factor (VEGF) and Matrix Metalloprotease
(MMP)-9 seem to play a dominant role in the initiation of
sprouting angiogenesis. Interestingly, not all exposed
endothelial cells are able to react to these stimuli. Only a
few cells, designated as tip cells, are selected for outgrowth
which ensures the maintenance of the pre-existing vessel
integrity [2] (Fig. 1).
In contrast to sprouting, intussusceptive angiogenesis is
a non-proliferative and non-invasive mechanism for the
enlargement of the capillary plexus. During intussusception
three major phases can be observed: intussusceptive
growth, intussusceptive arborisation and intussusceptive
remodelling (Fig. 1) [3]. Intussusceptive growth involves
the initiation of transluminal pillar formation originating
from the endothelial cell walls and their subsequent
expansion resulting in the splitting of the existing vessel
into two, thereby enhancing the vascular surface. Arborisa-
tion circumscribes the process of serial pillar formation
which remodels the disorganized capillary network into a
functional tree-like structure. Finally, the optimal adaptation
Figure 1 Diagram illustrating
the mechanisms of blood vessel
formation. Vasculogenesis and
sprouting generate a primitive
capillary plexus in an avascular
tissue. As soon as the newly
formed vessels are perfused,
intussusception is triggered and
is responsible for rapid capillary
growth and expansion. Feeding
vessels are subsequently segre-
gated from the capillary plexus
by intussusceptive arborization
and finally the intussusceptive
branching remodeling and
vascular pruning optimize
branching geometry and form
the final vascular pattern
(adapted from [77])
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of the vascular geometry to the local needs is achieved
during remodelling and involves the modification of
branching angles and often the re-dimension of the
capillary network by vascular pruning. Evidence gained
from various vasularization model systems suggests that
angiogenesis is mostly initiated by sprouting. Intussuscep-
tive growth follows during the maturation phase and
enables the fine-tuning and final spatial organization of
the newly formed vascular network [4]. In contrast to
sprouting angiogenesis, only limited information regarding
the control of intussusception is available. Shear stress on the
vessel walls has been suggested as one inducer of intussus-
ceptive growth. Interestingly, this only holds true for laminar
shear stress (in parallel to the vessel wall) while oscillating
shear stress is involved in the induction of sprouting
angiogenesis. Molecularly, VEGF and angiopoietin-1 are
likely to synergistically regulate intussusceptive vascular
expansion [4].
Vasculogenesis, the de novo formation of blood
capillaries, has long been thought to be restricted to
embryonic development. Only recently has it become
evident that this process also contributes to vascular
expansion post-natally. In the adult, haematopoietic stem
cells, myeloid cells, side population cells of the bone
marrow as well as tissue-resident pluripotent stem cells
can be induced to differentiate into endothelial progenitor
cells. These endothelial progenitors evade the stem cell
niche and migrate to their place of destination where they
proliferate and differentiate into blood capillaries (Fig. 1)
[5]. The regulation of adult vasculogenesis is just starting
to be investigated. Again, VEGF has been identified as
key factor in the recruitment of endothelial progenitor
cells from the bone marrow [6]. In addition, induction of
MMP-9 and cathepsin-G expression results in the detach-
ment of stem cells from their niche and in the cleavage of
matrix-bound growth factors required for their differenti-
ation to the endothelial lineage [7]. Interestingly, it
has recently been shown that estrogen is able to
mobilize inactive endothelial precursor cells and initiate
neovascularization [8].
The Microvasculature During Mammary Gland
Development
In the mouse, the vasculature of the mammary glands in
mature virgin females is composed of a capillary plexus
which runs in parallel or encircles the mammary parenchy-
ma and ramifies throughout the adipose tissue. Mammary
corrosion casts revealed an extensive expansion of the
vasculature and an increase in the number of capillaries
during pregnancy. The presence of numerous capillary
sprouts during the first half of pregnancy indicates that
vascular growth is initiated by sprouting angiogenesis.
After day 14 of pregnancy, capillary sprouts disappear and
the progressive occurrence of capillary pillars implies that
during the last third of pregnancy and early lactation the
vascular expansion switches from sprouting to intussuscep-
tion. Furthermore, the honey-comb-like architecture of the
capillaries enveloping a single alveolus, typical for the
lactating gland, is initiated concomitantly with the switch in
the angiogenic mode [9]. These observations suggest that
mammary angiogenesis is mainly accomplished by sprout-
ing and intussusception. It remains to be investigated
whether de novo vasculogenesis from mesenchymal pre-
cursor cells may also contribute to the vascular expansion.
It is well documented that the adipose tissue contains a
stem cell fraction which is capable of differentiating into
endothelial cells, being incorporated into capillary struc-
tures and contributing to vessel formation [10, 11].
Considering the large extent of adipose tissue in the
quiescent adult mouse mammary gland, it is conceivable
that this angiogenic mechanism might be effective at least
at the beginning of pregnancy. Interestingly, not only does
the extent of the vasculature increase during pregnancy, but
also the individual endothelial cells increase their surface
by the formation of numerous microvillous processes and
marginal folds. Moreover, the endothelial cells exhibit an
elevated number of mitochondria and pinocytotic vesicles
as well as decreased cell-cell contacts thereby enabling the
highly efficient transport of nutrients and fluids required
during lactation [12, 13].
The secretory epithelium regresses by apoptotic cell
death after lactation. The endothelium also regresses to the
extent found in the quiescent mammary gland of adult
female mice. Although the mechanisms of controlled
vascular regression would have a major impact on
angiogenesis-based therapeutic concepts, much remains
unknown about the mechanism of vascular regression
during mammary involution. Based on morphological
criteria, apoptotic cell death is observed in endothelial cells
although this may only partially account for the remodel-
ling of the vasculature [14]. Interestingly, vascular obstruc-
tion and endothelial cell death peak around day 6 of
involution, when epithelial cell death ceases and is replaced
by tissue remodelling. This timing indicates that tissue
reconstruction is initiated by the epithelium and the
vasculature adapts to the altered environment [9].
In contrast to the rodent and bovine (reviewed in [15])
systems, little is known about vascularization of the human
breast. For obvious reasons, developmental studies on the
extent of the vasculature are hardly possible in the human
breast and thus, only one detailed morphometric study
exists in humans for breast tissue obtained from premeno-
pausal women in the follicular phase of the estrous cycle
[16]. In this study, the authors demonstrate that the
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mammary epithelium exhibits two different patterns of
microvascularization. Ductal structures were found to be
surrounded by a high number of small capillaries often
without an identifiable lumen. In contrast, the acini of
lobular structures were interspersed by fewer capillaries
which, however, were significantly larger and sinusoidal in
shape. This vascular geometry favours a slower blood flow
and thereby a prolonged contact of the lobular epithelium
with the circulating hormones.
The Control of Mammary Vascularization
VEGF
The formation of new blood vessels is tightly controlled by an
array of stimulatory and inhibitory growth factors and
hormones. VEGF (also termed VEGF-A) is the first member
of pro-angiogenic cytokines identified and belongs to the
heparin-binding growth factor family which includes VEGF-
B, VEGF-C, VEGF-D and placental-like growth factor.
VEGF-A, subsequently termed VEGF, represents the pre-
dominant pro-angiogenic factor and exists in several splice
variants (VEGF121, VEGF145, VEGF165, VEGF189 and
VEGF206 in humans), each exhibiting slightly different
biological activities and sub-cellular localizations [17]. In
addition, an alternative splicing distal of exon 8 results in the
VEGFXXXb isoforms which exert anti-angiogenic effects
[18]. Full-length VEGF plays a pivotal role in the induction
of endothelial proliferation, migration and vascular perme-
ability [17]. Thus, it has to be postulated that VEGF is also
instrumental in the regulation of the mammary vasculature.
Indeed, VEGF expression has been found to be differentially
regulated at the transcriptional level in the mammary gland
during pregnancy and lactation [19, 20]. It has been shown
that the VEGF protein is produced in the alveolar epithelial
cells and that protein expression levels increase with the
onset of pregnancy, peak at late gestation and gradually
decrease during lactation and involution [21]. Two reports
have addressed the role of parenchymal VEGF expression
during mammary gland development and function. In the
first report, transgenic mice exhibited a conditional knock-
out of VEGF in the mammary myoepithelium and epitheli-
um. The VEGF knock-out led to a severe inhibition of
lobulo-alveolar expansion during pregnancy and to impaired
secretory activity of the epithelial cells during lactation.
Interestingly, the microvascular density was not significantly
reduced in the absence of VEGF. However, the vessels
exhibited an almost complete loss of vascular permeability
[22]. The other report investigated the role of VEGF in
transgenic mice overexpressing VEGF165b in the mammary
epithelium during pregnancy and lactation. VEGF165b is a
splice variant of VEGF which competes with VEGF for
receptor binding and elicits a strong anti-angiogenic re-
sponse. The inhibition of VEGF function in the transgenic
animals led to a comparable phenotype of the mammary
epithelium i.e. reduced alveolar development and lactational
failure. In contrast to the VEGF knock-out, however, the
vascular density was significantly reduced in the VEGF165b
transgenic mice [18]. This difference can be explained by the
fact that in the first approach VEGF expression was
abolished only in the parenchyma and the other cell types
present in the mammary tissue may have ensured a sufficient
level of VEGF expression to stimulate endothelial growth. In
contrast, a dominant negative mutant was secreted by the
mammary epithelium in the VEGF165b transgenic mice
leading to an inhibition of extracellularly present VEGF,
and consequently, a reduction in vascular outgrowth.
Expression of VEGF and its induction of angiogenesis
is mainly induced by the heterodimeric transcription
factor hypoxia inducible factor-1 (hif-1). The hif-1α
subunit is the regulatory partner which under normoxid
conditions is rapidly degraded. Under hypoxic conditions
hif-1α is stabilized and its transcription increased [23].
The role of hif-1α in the regulation of mammary gland
vascularization has been addressed in transgenic mice
exhibiting a complete hif-1α gene knock-out in the
mammary epithelium [24]. Interestingly, abolishing the
function of hif-1α did not result in a decrease of vascular
expansion at pregnancy and the capillary network at
lactation was comparable to that of wild type mice.
Although primary epithelial cells of the hif-1α null
females showed a drastic reduction of VEGF expression
after exposure to hypoxia, the overall VEGF concentration
was normal in the intact mammary glands. The loss of hif-
1α function in the epithelium, however, led to a severe
impairment of alveolar expansion and differentiation
during pregnancy, to impaired lipid and milk protein
secretion and thus to lactation failure. This phenotype
closely resembles the effects observed after VEGF knock-
out in the mammary gland. Although not directly
addressed in this report, it is likely that after the hif-1α
knock-out VEGF expression was induced by other
mechanisms to stimulate vascular outgrowth (see below),
but that the absence of hif-1α led to an impairment of
vascular structure and function.
These results demonstrate not only that VEGF and hif-
1α have a crucial function in regulating the mammary
vasculature but also that the proper development and
functioning of the secretory epithelium is dependent on a
well-developed, functional vasculature.
Estrogen and Progesterone
Estrogen and progesterone are of primary importance for
mammary epithelial development during puberty, the
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estrous cycle and pregnancy. Whereas estrogen is mainly
involved in ductal elongation and epithelial proliferation,
progesterone is instrumental in branching morphogenesis
and alveologenesis [25, 26]. Considering their pivotal role
in all aspects of mammary epithelial function, it is
conceivable that these hormones may also be involved in
the regulation of mammary vascularization. Indeed, it has
been shown that estrogen is involved in angiogenic
processes by two ways; by inducing the epithelium to
impart angiogenic stimulation [27] and by directly acting
on the endothelial cells [28].
The angiogenesis-related effects of estrogen on the
mammary epithelium involve its direct or indirect
regulation of pro- and anti-angiogenic factor production
by epithelial cells [27]. A direct target of estrogen is the
VEGF gene which contains a functional estrogen response
element in its promoter [29], where transcription can
directly be induced by estrogen in estrogen receptor-
positive cell lines [30]. During normal mouse mammary
gland development the highest VEGF levels have been
found at late pregnancy (see above) while in humans
VEGF levels increase two-fold during the luteal phase of
the estrus cycle [31]. Since these developmental windows
are characterized by high estrogen and progesterone
levels, progesterone may synergize with estrogen to
induce VEGF expression. Indeed, Wu and co-workers
have shown that VEGF induction by estrogen is dependent
on progesterone signalling via the progesterone receptor
B, probably by up-regulating the expression of estrogen
receptor-α [32]. In contrast to the direct activation of
VEGF expression, estrogen also indirectly enhances
VEGF production by inducing hif-1α expression and
recruiting Hif-1α to the VEGF promoter [33, 34]. The
transcription factor hexamethylene bisacetamid-inducible
protein 1 (HEXIM1) has been shown to interact with
estrogen receptor-α thereby decreasing its transcriptional
activity. Transgenic mice expressing a conditional
HEXIM1 knock-out mutant in the mammary gland show
increased Hif-1α and VEGF expression in the mammary
gland and exhibit a five-fold increase in vascularization at
lactation [35]. These results underscore the importance of
estrogen in the priming of mammary epithelial cells for
their induction of angiogenesis.
In addition to the mammary epithelium, endothelial
cells also possess estrogen receptors and are responsive
to estrogen [36]. Interestingly, not all endothelial cells in a
given capillary express the estrogen receptor and it
remains to be elucidated if the estrogen receptor-positive
cells represent the tip cells responsible for sprouting.
Estrogen itself does not induce the angiogenic response of
endothelial cells, but potentiates virtually every step
involved in angiogenesis such as endothelial proliferation,
migration, differentiation and assembly of mature capil-
laries [28]. Interestingly, estrogen is also involved in
endothelial relaxation and induction of E-selectin, inter-
cellular adhesion molecule (ICAM) and vascular adhesion
molecule (VCAM) expression, components that are in-
volved in the recruitment of immune cells to the site of
requirement, normally injury [28]. This aspect is of
particular interest in the context of mammary gland
development, since there is accumulating evidence that
peri-epithelial macrophages and leucocytes contribute
substantially to the establishment of a functional organ
structure [37].
Prolactin
In addition to steroid hormones, the proteohormone
prolactin is equally important in the regulation of mammary
epithelial proliferation, differentiation and milk protein
gene expression [38]. In addition to its effects on the
mammary epithelium, prolactin can also act as a stimula-
tory or inhibitory factor on growth, dilatation and remod-
elling of blood vessels. In its angiogenic function, prolactin
can act as a circulating hormone or in an auto/paracrine
fashion since, in addition to the pituitary gland; it is also
expressed by endothelial cells [39]. The full-length protein
is thought to promote angiogenesis, to alter the cytoskele-
ton and adhesive properties of endothelial cells and
probably to support vasoconstriction. It has to be empha-
sized that the data concerning the above-mentioned effects
are highly controversial suggesting that vascular networks
at different locations may respond very differently to the
hormonal stimulation [40]. In addition, it is not known if
prolactin acts directly or indirectly on the endothelial cells,
since endothelial cells from different locations differ in the
presence and constellation of prolactin receptor isoforms on
the cell surface [41–43]. So far, no data are available
addressing the direct response of the mammary endotheli-
um to prolactin. Given these controversial observations, an
indirect effect of prolactin on mammary angiogenesis may
seem more likely, since prolactin has been shown to
enhance the expression of VEGF in a variety of cell types
including mammary epithelial cells [44].
In contrast to its stimulatory effect, the inhibition of
angiogenesis by prolactin is well documented. Proteolytic
cleavage of prolactin results in prolactin fragments ranging
from 14 to 18 kDa, also known as vasoinhibins [45].
Cathepsin D was the first enzyme identified that was able to
generate vasoinhibins [46]. Thereafter, several members of
the MMP family as well as bone morphogenic factor 1-like
metalloproteases were shown to process prolactin to vaso-
inhibins [47, 48]. Vasoinhibins act directly on the endothe-
lial cells and inhibit growth factor-dependent proliferation,
migration as well as tube formation and induce endothelial
apoptotic cell death [40]. In the context of the mammary
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gland, cathepsin D-induced generation of vasoinhibins may
be of particular interest regarding the observed attenuation
of vascular expansion during lactation and regression
during involution. Cathepsin D is a member of the pepsin
family of proteases localized in lysosomes and endosomes
and is thought to be active at an acid pH [49]. It has been
shown, however, that lactating mammary epithelial cells
release cathepsin D which is able to generate vasoinhibins
at neutral pH outside the cells [50]. Interestingly, processing
and polarized secretion of cathepsin D seems to be
controlled by prolactin [51]. Cathepsin D is moderately
expressed in the rodent lactating mammary gland and
strongly induced 8 h after forced weaning. Moreover,
enzyme activity is substantially increased by nitration
2 days after weaning [52]. Thus, although cathepsin D has
been primarily implicated in the mitochondrial caspase-
dependent pathway of cell death [53], it may also be crucial
for vascular regression during involution through its ability
to generate vasoinhibins.
Eph-ephrins
The large family of Eph receptors and their membrane-
bound ligands play key roles in a vast variety of
morphogenic processes and adult tissue homeostasis.
Receptor-ligand interaction requires direct cell-cell contact
and elicits forward signaling form the receptor and reverse
signaling emanating from the ligand leading to bi-
directional cell-cell communication. Members of the Eph-
ephrin family, predominantly EphB4 and ephrin-B2, have
been implicated not only in the development of the
embryonal vasculature but also in neo-vascularization in
the adult. Endothelial expression of EphB4 and ephrin-B2
mediate the critical communication between arterial and
venous endothelia whereas non-endothelial expression has
been implicated in endothelial cell guidance [54]. More-
over, EphB4 has a regulatory function in the switch from
sprouting to circumferential (endothelial proliferation with-
in the vessel wall) angiogenesis and in vascular permeabil-
ity [55]. Recent evidence also suggests that ephrin-B2 is
instrumental in the spatial activation of VEGF-receptor
internalization, thereby regulating the endothelial tip cell
filopodial extension [56, 57].
We have shown that EphB4 and ephrin-B2 are expressed
in the mammary parenchyma in a developmentally- and
hormonally-regulated manner [58]. In order to elucidate the
role of these two molecules in mammary gland biology, we
have generated transgenic mouse models overexpressing
EphB4 [59], ephrin-B2 or a dominant negative mutant of
ephrin-B2 capable of receptor stimulation but unable to
elicit reverse signalling [60] in the mammary epithelium.
Transgene expression led to distinct phenotypic consequen-
ces for the mammary epithelial architecture and function.
Most notably, overexpression of EphB4 and the dominant
negative ephrin-B2 mutant led to an incomplete outgrowth
of alveolar structures during pregnancy, to delayed differ-
entiation and to impairment of secretion. In contrast,
overexpression of the native ephrin-B2 gene resulted in
precocious alveolar differentiation during pregnancy and
increased secretory activity during lactation. Beside the
epithelium, distinct effects of epithelial transgene expres-
sion on the mammary vasculature have been observed. The
vasculature in the lactating mammary glands of transgenic
females overexpressing the native ephrin-B2 gene exhibited
the same organized honeycomb-like capillary structure
observed in wild type females. In contrast to the wild type
situation, however, the alveoli were not surrounded by a
single capillary layer but were enveloped by a bi- or even
multilayered capillary ring (Fig. 2a and b) [60]. As
observed for the epithelium, overexpression of EphB4 and
ephrin-B2 affected the vasculature in a highly comparable
manner. Lactating mammary glands of females from both
transgenic strains exhibited a highly irregular vasculature in
which the location of the alveoli was often barely
discernable. Moreover, a surplus of irregular capillaries
and many blind-ending capillary stumps were observed [60,
61] (Fig. 2c and d). These results indicate that intact
EphB4-ephrin-B2 signalling in the mammary epithelium is
indispensable for the proper organization and functioning
not only of the epithelium but also of the mammary
vasculature. Moreover, as observed in the VEGF or hif-1α
deficient mice, this model also emphasizes the correlation
between mammary epithelial functionality and adequate
development of the vasculature.
Angiogenesis and Mammary Tumor Progression
Nowadays it is common knowledge that blood vessel
formation is indispensable for cancer growth, invasion and
metastasis formation. As hyperplastic or tumor nodules
grow, they require their own vasculature in order to ensure
sufficient supply of nutrients and oxygen. The hypoxic
conditions in the tumor nodule or its adjacent stromal
tissue activate Hif-1α and thereby the secretion of
angiogenic factors [62]. Interestingly, not only hypoxia
but also solely the loss of cell polarity, a hallmark of
the transformation of hyperplastic lesions to cancer, is
sufficient to induce the expression of VEGF in mammary
epithelial cells [63]. The angiogenic switch from avascular
to vascularized tumors and the clinical importance of
angiogenesis in breast cancer diagnosis and treatment have
been summarized in three excellent recent review articles
[64–66]. Thus, in this review article we would like to
highlight just the aspect of angiogenic mechanisms in
mammary carcinogenesis.
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Although tumor angiogenesis has become a highly
investigated target for therapeutic intervention, relatively
little is known about the mode of angiogenesis in tumor
development. Most likely, the angiogenic switch originating
from the release of pro-angiogenic factors by the tumor
cells induces sprouting angiogenesis in the first place. We
have previously shown, however, that sprouting and
intussuceptive angiogenesis occur side by side in estab-
lished experimental mouse mammary tumors [9]. The mode
of tumor angiogenesis is not a purely semantic issue but is
of extreme importance regarding therapeutic approaches.
Therapeutic regimens today involve mainly chemotherapy
or irradiation. Blockers of angiogenesis, in combination or
as unique agents, are also increasingly applied in the clinic,
mostly involving agents blocking various components of
the VEGF-induced signaling pathway. Thus, the current
treatment concepts address fast dividing cells as the main
constituents of the tumor mass and as sites of sprouting
angiogenesis [65]. Although an initial response is achieved,
tumor recurrence is a common phenomenon regardless of
the chosen therapy. It has been shown that VEGF blocking
agents induce selective apoptosis in immature capillaries as
they are formed by sprouting angiogenesis. In contrast,
mature blood vessels, covered with peri-endothelial cells
such as smooth muscle cells or pericytes, are resistant to
VEGF withdrawal [67]. We have demonstrated that after
irradiation or VEGF receptor inhibition of MMTV-NeuT
induced mouse mammary tumors this remaining mature
vasculature is the origin of intussuceptive growth to restore
the hemodynamic and structural integrity of the vasculature
[68]. The transient switch of sprouting to intussuceptive
angiogenesis probably takes place during treatment or
immediately after its cessation. Tumor recurrence, observed
about 1 week after treatment cessation, coincides with a
switch to a second wave of sprouting angiogenesis. Thus,
intussuceptive angiogenesis represents a part of the tumor
protective adaptive response and may be a major reason for
tumor therapy resistance and tumor recurrence.
In addition to angiogenesis, increasing evidence suggests
that de novo vasculogenesis originating from endothelial
precursor cells recruited from bone marrow or adipose tissue
is also instrumental in experimental mouse and human breast
tumor vascularization. Attracted by chemokines such as
stromal derived factor (SDF)-1α, chemokine (C-C motif)
ligand (CCL)-2 and -5, precursor cells enter the tumor mass
and differentiate into vascular sprouts which are then
incorporated or connected to the in-growing vessels from the
pre-existing vasculature [69]. Interestingly, chemotherapeutic
or anti-angiogenic treatment leads to an acute and rapid
mobilization of endothelial precursor cells into the tumor
mass [70, 71]. Thus, in addition to the switch to intussu-
ception, the recruitment of endothelial precursor cells might
support the protective tumor response. In this respect, the
dietary uptake of linoleic acid may represent an alternative
route to inhibit the adaptive response. It has been shown that
linoleic acid not only inhibits angiogenesis but also prevents
the differentiation of adipose tissue-derived mesenchymal
stem cells into the endothelial pathway [72].
Ephrin-B2wild type
mutant ephrin-B2EphB4
ba
dc
Figure 2 Scanning electron
micrographs of mercox corro-
sion casts of the vasculature in
the lactating mammary glands of
wild type females (a) and trans-
genic females overexpressing
ephrin-B2 (b), EphB4 (c) or a
dominant negative ephrin-B2
mutant (d) in the mammary
epithelium. Arrows point to bi-
layered capillary rings and ar-
row heads indicate blind-ending
capillaries. Bars represent 25 μ
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Synopsis
From the knowledge gained to date it has become clear that
the presence of a precisely-developed vasculature is
imperative for the proper course of the mammary gland
cycle. In contrast to most other organs of the body, where
induction of angiogenesis occurs only in response to injury
and originates from the stroma, the mammary parenchyma
constantly regulates its own vasculature according to the
changing functional demands. The fact that the mammary
epithelium is able to regulate its own angiogenesis might be
a main reason why mammary cancer cells are able to
induce the angiogenic switch for their vascularization at a
very early state during carcinogenesis [73]. Interestingly,
among the different subtypes of breast cancer, the triple
negative breast cancers seem to be especially potent in the
induction of angiogenesis [66]. These triple negative breast
tumor cells share many characteristics with the basal
epithelial cells, where it is thought, that this progenitor cell
population is the origin of cancer. Thus, it is conceivable
that this cell population is also responsible for the initiation
of angiogenesis during normal development. As potent as
the mammary epithelium is in the induction of angiogen-
esis, it is equally potent in the induction of ordered vascular
regression during involution. Although of potential thera-
peutic importance, the regulation of vascular retraction has
so far received little attention. The observed decline in
VEGF expression during lactation and involution may be
instrumental in the attenuation of endothelial cell growth
but is unlikely to be the only factor responsible for the
massive reduction of the capillary network. Moreover, the
apparently-contradictory role of cathepsin D regulating
epithelial and endothelial regression, while also promoting
metastatic tumor growth is poorly understood. Thus,
deciphering the mechanisms involved in vascular retraction
remains a challenging task for the future.
Angiogenesis during normal and malignant mammary
epithelial development is induced by the epithelial secretion
of pro-angiogenic factors. This stimulates vascularization
which in turn supports epithelial proliferation and differenti-
ation. It has to be kept in mind, however, that the same factors
are also able to directly stimulate the epithelium itself. This is
evident for the hormones estrogen, progesterone and prolac-
tin, but it has also been shown that mammary epithelial cells
possess VEGF receptors and that VEGF can induce epithelial
cell proliferation in an autocrine manner [74, 75]. Moreover,
the observed phenotypic consequences of VEGF inhibition
in the mammary epithelium could also, at least partly, be
brought about by the inhibited autocrine stimulation leading
to the inhibition of epithelial proliferation and differentiation.
Thus, by applying an anti-angiogenic therapy in breast
cancer treatment, one may directly interfere with not only
the malignant but also the normal epithelial cell properties.
It is thought that the main purpose of angiogenesis is to
ensure a sufficient supply of oxygen and nutrients.
However, the alteration of endothelial cell properties, as
effected by the VEGF knock-out [22], was sufficient to
impair epithelial polarization and secretory differentiation.
This suggests that, in addition to allow nutrient supply,
endothelial cells may also directly be involved in the
regulation of the epithelium. This effect might be brought
about by inductive paracrine stimulation or by direct
epithelial-endothelial interactions. Indeed, Shekar et al.
demonstrated in 2000 that the interaction with endothelial
cells is a prerequisite for branching morphogenesis of
MCF10 human mammary epithelial cells and that, in turn,
the interaction supports endothelial growth and differenti-
ation [76]. Since then, however, no additional information
about the underlying inductive principle has become
available. The mammary epithelium is surrounded by a
sheet of myoepithelial cells and a basement membrane
which separates the epithelium from the stromal compart-
ment and a direct interaction of epithelial and endothelial
cells seems unlikely. If an endothelial-epithelial crosstalk
exists it is rather transmitted via the myoepithelium. There
are, however, developmental stages, such as the terminal
endbud during puberty or the lactating epithelium, where
the myoepithelial cell layer is discontinuous and a direct
interaction of epithelial cells with blood capillaries is
conceivable. Our observation that epithelial expression of
EphB4 or ephrin-B2 affects the development of the
vasculature during lactation supports the notion that direct
epithelial-endothelial interactions may be instrumental in
the establishment of a functional tissue architecture. If the
mutual interaction of epithelial and endothelial cells is
indeed a prerequisite for the function of both partners it
may also be instrumental for the support of tumor growth.
This, however, would open a whole range of new
therapeutic options. The blocking of these vital interactions
would not only reduce the viability of both partners but due
to the lack of intercellular communication might also
prevent the adaptive response.
Concluding Remark
It is generally accepted that the microenvironment plays a
crucial role for the proper development and functioning of the
mammary gland. Whereas the crosstalk between the paren-
chyma, mesenchyme and adipose tissue is under extensive
investigation, the importance of the vasculature, other than
providing nutrients, has so far gained little attention. The
vasculature, however, is likely to be of equal importance for
the homeostasis of the mammary epithelium as the other
stromal components. Thus, elucidation of the endothelial-
epithelial crosstalk and deciphering the inductive mechanisms
326 J Mammary Gland Biol Neoplasia (2010) 15:319–328
will not only broaden our understanding of mammary gland
development and physiology but also may offer new aspects
for targeted anti-breast cancer therapies.
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